Hjem › Ikke-småcellet lungekreft › North Dakota
Kliniske studier for Ikke-småcellet lungekreft i North Dakota
16 studier for Ikke-småcellet lungekreft søker deltakere på steder i North Dakota.
Byer i North Dakota
Offisiell studietekst (engelsk)
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- Essentia Health Cancer Center-South University Clinic, Fargo
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT07388524Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Sanford Bismarck Medical Center, Bismarck
- Sanford Broadway Medical Center, Fargo
- Sanford Roger Maris Cancer Center, Fargo
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT04267848A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
- Sanford Bismarck Medical Center, Bismarck
- Sanford Broadway Medical Center, Fargo
- Sanford Roger Maris Cancer Center, Fargo
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07293247A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Sanford Fargo Medical Center ( Site 3236), Fargo
- Altru Health System ( Site 3254), Grand Forks
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT07513376Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Sanford Bismarck Medical Center, Bismarck
- Essentia Health Cancer Center-South University Clinic, Fargo
- Sanford Broadway Medical Center, Fargo
- og 1 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT06498635A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0057), Fargo
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06312137A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Grand Forks
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 18. sep. 2026 · NCT06692738KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
- Sanford Fargo Medical Center ( Site 0039), Fargo
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 25. aug. 2026 · NCT04165798KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
- Sanford Fargo Medical Center ( Site 0039), Fargo
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. aug. 2026 · NCT04165070A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
- Sanford Fargo Medical Center ( Site 0039), Fargo
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 18. aug. 2026 · NCT06731907Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
- Sanford Roger Maris Cancer Center, Fargo
RekruttererFase 2
Alder 18 til 70 · Alle kjønn · Oppdatert 26. jun. 2026 · NCT04614103Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Sanford Bismarck Medical Center, Bismarck
- Sanford Broadway Medical Center, Fargo
- Sanford Roger Maris Cancer Center, Fargo
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 3. jun. 2026 · NCT05642572Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Sanford Bismarck Medical Center, Bismarck
- Essentia Health Cancer Center-South University Clinic, Fargo
- Sanford Broadway Medical Center, Fargo
- og 1 flere
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 5. mai 2026 · NCT06616584Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Sanford Bismarck Medical Center, Bismarck
- Sanford Broadway Medical Center, Fargo
- Sanford Roger Maris Cancer Center, Fargo
RekruttererFase 2
18 Minutes · Alle kjønn · Oppdatert 5. mai 2026 · NCT06031688Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Essentia Health Cancer Center-South University Clinic, Fargo
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 17. mar. 2026 · NCT06418204SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Fargo
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.